Onset Therapeutics (Onset) has reported positive results from a skin moisturisation study that compared the company’s recently launched BenzEFoam (benzoyl peroxide 5.3%) emollient foam to combination gel containing clindamycin 1% – benzoyl peroxide 5%.
BenzEFoam Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris and is the first prescription foam formulation containing benzoyl peroxide as the active ingredient.
Reportedly, the skin moisturisation study demonstrated that BenzEFoam’s emollient foam provides greater skin hydration than a currently marketed clindamycin 1% – benzoyl peroxide 5% gel at all time points over an 8-hour period post application.
The study was the first to evaluate the reduction of the acne-causing bacteria propionibacterium acnes (P Acnes) on the back after treatment with an acne medication. This study demonstrated that total P acnes colony counts on patients’ backs were reduced by >99% after 2 weeks of treatment with BenzEFoam. In contrast, a benzoyl peroxide 8% wash applied in the shower failed to significantly reduce P acnes counts on the back after two full weeks of treatment.
Doug Abel, general manager of Onset, said: “The BenzEFoam formulation is rich in emollients and humectants and was specifically tailored to maximise the cosmetic elegance and moisturisation properties of the product in an effort to increase patient compliance, which in turn can positively affect the efficacy of a product.
“With the launch of our website we are pleased to offer patients and physicians a new informational resource to assist them in managing mild to moderate acne vulgaris. The video discussions contained on the BenzEFoam website, led by dermatologists discussing the topical treatment of acne, provide an invaluable resource to our customers.”